WEST DES MOINES, Iowa, Sept. 1, 2016 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT) today announced that Cassandra K. MacArthur has joined the company as Senior Vice President of Regulatory Affairs and Compliance. Ms. MacArthur will be responsible for all aspects of regulatory affairs including strategic planning for regulatory approvals, preparation of regulatory submissions, serving as the primary contact with the FDA and other regulatory authorities, and compliance with all regulatory agencies worldwide.
Ms. MacArthur has thirty years of experience in basic research, biotech, biopharmaceuticals, and medical devices, including the development of small molecules, biologics, proteins, peptides, oligonucleotides, diagnostics, and medical device products. She has directed numerous successful regulatory submissions including New Drug Applications (NDAs), Investigational New Drug (IND) applications, Biologics License Applications (BLAs), and Abbreviated New Drug Applications (ANDA).
"I am pleased to be joining the team at this exciting stage of the Company's development and look forward to contributing to Spotlight Innovation's future success," commented Ms. MacArthur.
Ms. MacArthur has managed several domestic and international development projects including manufacturing sites for drug and oligonucleotide development, and an international anti-bioterrorism project. She began her career at the Salk Institute for Biological Studies and at Scripps Clinic for Biological Research, and has conducted research studies with several Nobel Laureates and a National Academy of Sciences member.
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.
Forward Looking Statements
Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technologies, the inability to hire appropriate staff to develop the technologies, unforeseen technical difficulties in developing the technologies, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise more preferable, the inability to market a product, all of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.